1 week Ago By Defense World Staff
American Century Companies Inc. grew its stake in Puma Biotechnology, Inc. ( NASDAQ:PBYI – Free Report ) by 8.
4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 948,376 shares of the biopharmaceutical company’s stock after acquiring an additional 73,833 shares during the quarter. American Century Companies Inc.
owned 1.93% of Puma Biotechnology worth $2,893,000 at the end of the most recent quarter. A number of other hedge funds have also modified their holdings of the company.
JPMorgan Chase & Co. increased its stake in Puma Biotechnology by 169.5% in the third quarter.
JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 30,499 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Puma Biotechnology by 83.
9% during the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 11,252 shares during the period. FMR LLC lifted its holdings in shares of Puma Biotechnology by 27.
1% during the 3rd quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 25,183 shares in the last quarter. Barclays PLC grew its position in shares of Puma Biotechnology by 146.
5% in the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 46,370 shares during the period. Finally, Franklin Resources Inc.
bought a new stake in Puma Biotechnology during the 3rd quarter worth approximately $41,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades Several research firms have recently weighed in on PBYI. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a report on Friday, February 28th.
StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 8th. Puma Biotechnology Trading Down 2.
4 % NASDAQ:PBYI opened at $2.83 on Tuesday. The company has a market cap of $140.
40 million, a P/E ratio of 5.90 and a beta of 1.34.
Puma Biotechnology, Inc. has a twelve month low of $2.23 and a twelve month high of $6.
06. The business has a 50 day moving average price of $3.10 and a two-hundred day moving average price of $2.
99. The company has a quick ratio of 1.40, a current ratio of 1.
42 and a debt-to-equity ratio of 0.46. Puma Biotechnology ( NASDAQ:PBYI – Get Free Report ) last announced its earnings results on Thursday, February 27th.
The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.
29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.
60%. The business had revenue of $59.10 million during the quarter, compared to analysts’ expectations of $52.
50 million. As a group, analysts expect that Puma Biotechnology, Inc. will post 0.
31 EPS for the current fiscal year. Puma Biotechnology Profile ( Free Report ) Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Recommended Stories Five stocks we like better than Puma Biotechnology Growth Investing: Should You Adopt This Investing Strategy in 2022? Options Activity Points to More Volatility for Palantir Stock Canada Bond Market Holiday: How to Invest and Trade NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? What is the Dogs of the Dow Strategy? Overview and Examples MicroStrategy Sees Insider Buy-Sell Action in Q1 Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter ..
